164 related articles for article (PubMed ID: 38291048)
1. NPAS2 dampens chemo-sensitivity of lung adenocarcinoma cells by enhancing DNA damage repair.
Zhang Y; Chen Y; Huang W; Zhou Y; Wang Y; Fu K; Zhuang W
Cell Death Dis; 2024 Jan; 15(1):101. PubMed ID: 38291048
[TBL] [Abstract][Full Text] [Related]
2. Characterization of molecular subtypes based on chromatin regulators and identification of the role of NPAS2 in lung adenocarcinoma.
Huang Y; Xiao L; Daba MY; Xu D; Wang Y; Li L; Li Q; Liu B; Qin W; Zhang H; Yuan X
Clin Epigenetics; 2023 Apr; 15(1):72. PubMed ID: 37120564
[TBL] [Abstract][Full Text] [Related]
3. NPAS2, transcriptionally activated by ARRB1, promotes the malignant behaviours of lung adenocarcinoma cells and regulates the reprogramming of glucose metabolism.
Wang S; Huang C; Zheng Y; Wu X; Zhong Y
Clin Exp Pharmacol Physiol; 2024 May; 51(5):e13860. PubMed ID: 38584327
[TBL] [Abstract][Full Text] [Related]
4. SNHG15 enhances cisplatin resistance in lung adenocarcinoma by affecting the DNA repair capacity of cancer cells.
Li Y; Huang HQ; Huang ZH; Yu ND; Ye XL; Jiang MC; Chen LM
Diagn Pathol; 2023 Mar; 18(1):33. PubMed ID: 36864456
[TBL] [Abstract][Full Text] [Related]
5. Ring finger protein 6 enhances chemo-resistance by transcriptionally activating proliferating cell nuclear antigen expression and attenuating DNA damage in lung adenocarcinoma.
Sun Y; Sun H; Qi Y; Pan M; An N; Leng X; Liu Y; Chen Z
Cancer Lett; 2022 May; 534():215609. PubMed ID: 35278611
[TBL] [Abstract][Full Text] [Related]
6. Transcriptional factor MAZ promotes cisplatin-induced DNA damage repair in lung adenocarcinoma by regulating NEIL3.
Wang T; Zhu X; Wang K; Li J; Hu X; Lin P; Zhang J
Pulm Pharmacol Ther; 2023 Jun; 80():102217. PubMed ID: 37121465
[TBL] [Abstract][Full Text] [Related]
7. The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response.
Hoffman AE; Zheng T; Ba Y; Zhu Y
Mol Cancer Res; 2008 Sep; 6(9):1461-8. PubMed ID: 18819933
[TBL] [Abstract][Full Text] [Related]
8. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
9. Golgi Phosphoprotein 3 Confers Radioresistance via Stabilizing EGFR in Lung Adenocarcinoma.
Chen G; Kong P; Yang M; Hu W; Prise KM; Yu KN; Cui S; Qin F; Meng G; Almahi WA; Nie L; Han W
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1216-1228. PubMed ID: 34838866
[TBL] [Abstract][Full Text] [Related]
10. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
11. Identification of the key DNA damage response genes for predicting immunotherapy and chemotherapy efficacy in lung adenocarcinoma based on bulk, single-cell RNA sequencing, and spatial transcriptomics.
Sun S; Wang K; Guo D; Zheng H; Liu Y; Shen H; Du J
Comput Biol Med; 2024 Mar; 171():108078. PubMed ID: 38340438
[TBL] [Abstract][Full Text] [Related]
12. TRIM44 promotes BRCA1 functions in HR repair to induce Cisplatin Chemoresistance in Lung Adenocarcinoma by Deubiquitinating FLNA.
Zhang S; Cao M; Yan S; Liu Y; Fan W; Cui Y; Tian F; Gu R; Cui Y; Zhan Y; Sun Y; Xing Y; Cai L; Song Y
Int J Biol Sci; 2022; 18(7):2962-2979. PubMed ID: 35541909
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
14. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Xiao Y; Lin FT; Lin WC
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33408251
[TBL] [Abstract][Full Text] [Related]
15.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
16.
Wang Z; Zhou L; Chen B; Li X; Zou Q; Xu W; Fang L; Wu A; Li Z; Chen Y
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107669
[TBL] [Abstract][Full Text] [Related]
17. PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1.
Yu S; Li Y; Ren H; Zhou H; Ning Q; Chen X; Hu T; Yang L
Cancer Chemother Pharmacol; 2021 Feb; 87(2):207-215. PubMed ID: 33221963
[TBL] [Abstract][Full Text] [Related]
18.
Jiang F; Shen Q; Zhang F; Fu J; Hu L; Wang J; Zhou H; Chen J; Wang Y
DNA Cell Biol; 2022 Jun; 41(6):631-640. PubMed ID: 35612423
[TBL] [Abstract][Full Text] [Related]
19. DNA damage responsive miR-33b-3p promoted lung cancer cells survival and cisplatin resistance by targeting p21
Xu S; Huang H; Chen YN; Deng YT; Zhang B; Xiong XD; Yuan Y; Zhu Y; Huang H; Xie L; Liu X
Cell Cycle; 2016 Nov; 15(21):2920-2930. PubMed ID: 27559850
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of replication protein A 3 induces protective autophagy and enhances cisplatin sensitivity in lung adenocarcinoma by inhibiting AKT/mTOR signaling via binding to cyclin-dependent kinases regulatory subunit 2.
Chen L; Hu K; Liu Y; Liu L; Tang J; Qin X
Drug Dev Res; 2022 Nov; 83(7):1589-1599. PubMed ID: 35903032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
